Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 1998

View Archived Issues

Ergo Science meets with FDA regarding Ergoset

Digene awarded SBIR grant for HSV test development

Scriptgen and Lilly expand drug discovery collaboration

Anesta signs Actiq partnership with Lafon

Clinical trial results for DUROS leuprolide implant announced at AUA meeting

Immunex's CD40 Ligand enters phase I

Affymetrix and Human Genome Sciences to develop bacterial GeneChip probe arrays

Novopharm Biotech completes patient enrollment for GPI-2A phase Ia trial

Clarithromycin licensed to Boehringer Ingelheim for Latin America

Ixion receives notice of allowance for bacterial detection technology

Demeter BioTechnologies awarded U.S. patent for peptide technology

Magainin: Q1 1998 highlights

Ribi ImmunoChem: Q1 1998 highlights

GlycoDesign starts phase II trial of GD0039 for the treatment of RCC

New and established treatments for BPH reviewed at AUA

Controlled trial of rhGH in patients with dilated cardiomyopathy and chronic heart failure

Ribozyme obtains license to sickle cell anemia treatment technology

Ibutilide compared to other antiarrhythmic agents for effects on typical atrial flutter

Rosiglitazone and troglitazone exert differential effects on small arteries in vitro

U.S. patent issued covering aerosolized gene delivery using cationic lipids

Miravant and Xillix Technologies enter early-stage cancer collaboration

AHP reports dopamine autoreceptor agonists with antipsychotic potential

Crambescidin 816, an antiviral and antitumor agent from a marine sponge

DVT imaging agent enters phase II in Canada

Latanoprost compared to unoprostone in monkeys with glaucoma

Fuisz and Boehringer Ingelheim agreement for CEFORM EA technology

Alpha-Beta Technology receives grants for antifungal drug discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...